This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Laboratory tests for HIV infection

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The laboratory diagnosis of HIV infection is usually made on the basis of serology - detection of HIV antibody i.e. the detection of HIV-1/2 antibodies or simultaneous detection of HIV-1/2 antibodies and HIV-1 p24 antigen

  • most widely used means of diagnosing HIV
  • results are reported as non-reactive or reactive
  • generally classified as either
    • first-line assays (sometimes referred to as screening assays)
      • can provide the presumptive identification of reactive specimens and thus should have superior sensitivity e.g -
        • enzyme linked immunosorbent assay (ELISA)/enzyme immuno assay (EIA) test
        • rapid HIV tests/point-of-care tests (POCTs)
          • oral fluid or pin prick blood samples can be used
          • results can be given within minutes of the specimen being taken
          • specificity is lower than laboratory tests
          • all “reactive” POCT tests should be confirmed with a conventional blood test
        • simple assays e.g. – combo immunoassays and particle or latex agglutination assays that detect the presence of HIV-1/2 antibodies and/or HIV-1 p24 antigen.
    • second or third-line assays (sometimes referred to as supplemental assays, or confirmatory assays)
      • a combination of rapid HIV tests, simple assays and EIAs can be used as second- and third-line assays to confirm an initial reactive test result
      • in addition, line immunoassays (LIAs), based on recombinant proteins and/or synthetic peptides capable of detecting antibodies to specific HIV-1 and/or HIV-2 proteins, have been widely used to confirm HIV infection.
        • line immunoassays have replaced Western blotting n many settings and serve a similar purpose (1,2)

In addition HIV infection can also be diagnosed by detecting the presence of the virus itself.

  • presence of the virus itself
    • p24 antigen
      • 4th generation combination test is used to detect p24 antigen
  • presence of its genetic material (DNA PCR, viral load)
    • RNA/DNA polymerase chain reaction tests
      • these quantitative assays are a form of Nucleic Acid Amplification Test (NAAT)
      • not often used as an initial diagnostic test for HIV in adults as they are expensive and can risk a high false positive rate in the absence of laboratory interpretation
      • preferred test of specialists if primary HIV infection is suspected and the antibody/antigen test is negative
    • viral load
      • primarily used for monitoring antiretroviral treatment, but have been validated by many labs as a supplemental test during the window period of HIV infection (2,3)

Patients who identify a specific risk occurring more than 4 weeks previously should be offered a 4th generation HIV test immediately without waiting for 3 months (12 weeks).

  • a negative test will exclude HIV infection in majority of patients
  • additional test should be offered at 3 months (12 weeks) to all patients to exclude HIV infection definitively
  • low risk patients may wait for 3 months to avoid doing the test twice (4)

HIV antibody tests are used for diagnosis and screening.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.